RELAPSE MULTIPLE MYELOMA
Clinical trials for RELAPSE MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSE MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSE MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR t combo takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a One-Two drug punch beat back Hard-to-Treat myeloma?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New study examines belantamab combos for myeloma relapse
Knowledge-focused Not yet recruitingThis observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Sponsor: PETHEMA Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC